HSC01
clear graphic clear graphic
clear graphic

Gustavo Roman, M.D., elected to international neurology board

Posted: Friday, December 12, 2008

Share |

clear graphicclear graphic
clear graphicclear graphic
clear graphicEmail Printer Friendly Format
 

Contact: Karen Stamm, (210) 450-2020, (210) 621-7592 (cell)

SAN ANTONIO (Dec. 10, 2008) — Gustavo C. Roman, M.D., professor of neurology at The University of Texas Health Science Center at San Antonio, has been elected to the board of directors of The World Federation of Neurology (WFN).

To be nominated as a trustee, candidates must have a national and international reputation in neurology and demonstrate a substantial commitment to the growth and development of the WFN. For more than 10 years, Dr. Roman has served as associate editor of the organization’s Journal of the Neurological Science, chaired its research group on neuroepidemiology, and worked on a number of its research groups and committees.

The World Federation of Neurology is the international body representing the specialty of neurology in more than 100 countries and regions of the globe, with 108 member societies. Its purpose is to improve human health worldwide by promoting prevention and care of persons with disorders of the nervous system.

Dr. Roman founded in 1999 the UT Medicine San Antonio “Memory Disorders Clinic,” where he sees patients with Alzheimer’s disease, stroke and dementia. He is an advocate for research on the relationships between brain circulation and dementia.

###

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI)-Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug studies program in the world. IDD has participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.uthscsa.edu.

 
bottom bar

»printer friendly format...
»view more articles by issue#...
»search articles by keywords...
Arrow - to top
Arrow - to top